IBI363 + chemotherapy

DRUG4 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd., Zhejiang Cancer Hospital, Ruijin Hospital, Shanghai Pulmonary Hospital, Shanghai, China

Conditions

Advanced MalignanciesCarcinoma, Non-Small-Cell Lung Cancer (NSCLC)IBI363 + ChemotherapyPancreatic Cancer MetastaticUnresectable Stage III Non-small Cell Lung Cancer

Phase 1

A Study of IBI363 in Subjects With Advanced Malignancies

RecruitingNCT06468098

Innovent Biologics (Suzhou) Co. Ltd.Advanced Malignancies

Start: 2024-06-15End: 2026-12-31Target: 556Updated: 2024-07-18

Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Not yet recruitingNCT07342725

Ruijin HospitalPancreatic Cancer Metastatic

Start: 2026-01-01End: 2028-12-31Target: 48Updated: 2026-01-15

Phase 2

Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

RecruitingNCT07325630

Zhejiang Cancer HospitalIBI363 + Chemotherapy

Start: 2025-11-03End: 2027-12-31Target: 60Updated: 2026-01-08

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

RecruitingNCT07408635

Shanghai Pulmonary Hospital, Shanghai, ChinaCarcinoma, Non-Small-Cell Lung Cancer (NSCLC), Unresectable Stage III Non-small Cell Lung Cancer

Start: 2026-01-07End: 2030-01-06Target: 43Updated: 2026-02-13

Related Papers

IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).

Journal of Clinical Oncology2026-05-28